SPRY
Income statement / Annual
Last year (2023), ARS Pharmaceuticals, Inc.'s total revenue was $30,000.00,
a decrease of 97.72% from the previous year.
In 2023, ARS Pharmaceuticals, Inc.'s net income was -$54.37 M.
See ARS Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
Operating Revenue |
$30,000.00
|
$1.32 M
|
$5.51 M
|
$17.84 M
|
$0.00
|
$0.00
|
Cost of Revenue |
$73,000.00 |
$17.32 M |
$20.27 M |
$14.07 M |
$1.55 M |
$1.42 M |
Gross Profit |
-$43,000.00 |
-$16.00 M |
-$14.77 M |
$3.77 M |
-$1.55 M |
-$1.42 M |
Gross Profit Ratio |
-1.43 |
-12.16 |
-2.68 |
0.21 |
0 |
0 |
Research and Development
Expenses |
$20.27 M
|
$18.38 M
|
$20.27 M
|
$14.07 M
|
$21.51 M
|
$14.80 M
|
General & Administrative
Expenses |
$47.28 M
|
$18.46 M
|
$4.69 M
|
$4.23 M
|
$0.00
|
$0.00
|
Selling & Marketing
Expenses |
-$73,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$47.21 M
|
$18.46 M
|
$4.69 M
|
$4.23 M
|
$1.02 M
|
$2.10 M
|
Other Expenses |
$13.16 M |
$974,000.00 |
-$789,000.00 |
-$596,000.00 |
$0.00 |
$0.00 |
Operating Expenses |
$67.48 M |
$36.83 M |
$24.96 M |
$18.30 M |
$22.52 M |
$16.90 M |
Cost And Expenses |
$67.55 M |
$36.83 M |
$24.96 M |
$18.30 M |
$24.07 M |
$18.32 M |
Interest Income |
$0.00 |
$600,000.00 |
$800,000.00 |
$400,000.00 |
$100,000.00 |
$43,000.00 |
Interest Expense |
$0.00 |
-$834,000.00 |
$106,000.00 |
$29,000.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$73,000.00
|
$319,000.00
|
$213,000.00
|
$1.71 M
|
$1.55 M
|
$1.42 M
|
EBITDA |
-$67.45 M
|
-$35.06 M
|
-$19.45 M
|
-$463,000.00
|
-$22.52 M
|
-$16.90 M
|
EBITDA Ratio |
-2248.23 |
-26.64 |
-3.53 |
-0.03 |
0 |
0 |
Operating Income Ratio
|
-2250.67
|
-26.99
|
-3.53
|
-0.03
|
0
|
0
|
Total Other
Income/Expenses Net |
$13.16 M
|
$834,000.00
|
-$789,000.00
|
-$596,000.00
|
$100,000.00
|
$741,000.00
|
Income Before Tax |
-$54.37 M |
-$34.68 M |
-$20.24 M |
-$1.07 M |
-$23.97 M |
-$17.58 M |
Income Before Tax Ratio
|
-1812.17
|
-26.35
|
-3.68
|
-0.06
|
0
|
0
|
Income Tax Expense |
-$94,895.00 |
-$694,000.00 |
-$230,558.00 |
-$200,297.00 |
$0.00 |
$0.00 |
Net Income |
-$54.37 M |
-$33.99 M |
-$20.24 M |
-$1.07 M |
-$23.97 M |
-$17.58 M |
Net Income Ratio |
-1812.17 |
-25.83 |
-3.68 |
-0.06 |
0 |
0 |
EPS |
-0.57 |
-0.85 |
-0.7 |
-0.0307 |
-0.72 |
-0.53 |
EPS Diluted |
-0.57 |
-0.85 |
-0.7 |
-0.0307 |
-0.72 |
-0.53 |
Weighted Average Shares
Out |
$95.22 M
|
$39.96 M
|
$28.87 M
|
$34.70 M
|
$33.07 M
|
$33.07 M
|
Weighted Average Shares
Out Diluted |
$95.22 M
|
$39.96 M
|
$28.87 M
|
$34.70 M
|
$33.07 M
|
$33.07 M
|
Link |
|
|
|
|
|
|